Bubendorf, Switzerland, Sunday, December 6, 2020 – CIS Pharma has successful up-scaled the production of its novel contact lens multipurpose and disinfection solution (MPDS) to an industrial setup. The contact lens care solution achieved excellent performance compared to products that are leading the markets. From an efficacy perspective, the antimicrobial performance against various bacteria & fungi was tested according to ISO 14729. The primary criteria were reached within 2-4 hours, indicating the complete killing of the challenged organism. These criteria were met much faster than the 8 hours requested by ISO. From a comfort perspective, the release of the comfort agent hyaluronic acid (HA) from contact lenses soaked in the CIS Pharma product showed a long-lasting effect with up to four times higher release values compared to market-leading products, even after 24 hours. The solution also demonstrated excellent performance in a XTT cytotoxicity test according to ISO 10993-5 as no toxic effects were seen on a mouse skin fibroblast cell line (L929) up to the highest tested concentration. In summary, these results confirm increased biocompatibility of the novel formulation while comprising an unsurpassed concentration of hyaluronic acid and a powerful synergistic disinfection complex.